soul semaglutide trial oral cardiovascular outcomes 2024 2025 nejm SOUL: Oral Semaglutide Bests Usual Care in ACC 25 Late-Breaking Discussion: SOUL:

Given that GLP1s can cost hundreds of dollars per month, those figures translate into a substantial outofpocket burden for many users, and a material claims cost for both public and private plans where cover exists

Any regulatory framework that focuses on the molecule without addressing the source is missing where most of the actual harm comes from, he said

Clinical Evidence Summary Study Type: Retrospective analysis (not a randomized controlled trial) Participants: 1,131 program completers with BMI 30 Duration: 52-68 weeks Primary Outcome: 19.5% average body weight reduction at 52 weeks Medication: 95.4% compounded semaglutide, 4.6% branded semaglutide Control Group: None Funding/Authors: Ivm Health-affiliated authors (conflict of interest disclosed) Publication: Obesity Pillars , 2025 (PubMed indexed, peer-reviewed) Key Limitation: Self-selected completers

Kaiser Family Foundation (2024)